Targeting prostate cancer stem cells to delay prostate cancer progression
Targeting prostate cancer stem cells to delay prostate cancer progression
批准号:
8286889
负责人:
JIN-RONG ZHOU
金额:
$22.71万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2014-06-30
关键词:
AblationAmericasAndrogen ReceptorAndrogensB-Cell LymphomasBackBlack TeaCancer EtiologyCellsCessation of lifeComplement Factor BDown-RegulationDrug resistanceEpigallocatechin GallateGene ExpressionGenesGoalsHormonalHormonesLNCaPMalignant neoplasm of prostateMetastatic toMolecularNatureNeoplasm MetastasisPathway interactionsPatientsPhenotypePlayPreventiveProstateProstate Cancer therapyProstatic NeoplasmsPublic HealthRecurrenceRefractoryRegimenResearchResearch PriorityResistanceRoleSamplingSecond Primary NeoplasmsStagingStem cellsTestingTheaflavinsTherapeuticTherapeutic UsesTimeUp-Regulationandrogen independent prostate canceranticancer researchbasecancer cellcancer stem cellclinically relevantconventional therapydeprivationeffective therapyhormone refractory prostate cancerin vivoin vivo Modelmennoveloverexpressionreceptor expressionresponseself-renewalstemnesstherapeutic developmenttherapy developmenttranscription factortumortumor initiationtumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Due to the androgen-dependent nature of the vast majority of prostate cancer cells, androgen deprivation remains the primary therapeutics for androgen-dependent prostate cancer, and most patients respond initially to the treatment. However, with time, the majority of patients eventually develop more aggressive, androgen- independent and hormone-refractory tumors. Thus the search for mechanism-based therapeutic strategies that can delay hormone ablation-induced prostate cancer progression remains the top priority in prostate cancer research. Cancer stem cell (CSC) hypothesis suggests that CSCs have the ability to self-renew and differentiate and are responsible for tumor initiation, progression, drug resistance, recurrence and metastasis. However, it is unclear how prostate CSCs may respond to hormone ablation treatment and if prostate CSCs can be an effective target for inhibiting prostate progression. Our preliminary studies showed that prostate CSCs had overexpression of the stem cell self-renewal marker, the transcription factor B lymphoma Mo-MLV insertion region 1 (Bmi-1), that black tea significantly delayed androgen ablation-induced progression of prostate tumors associated with downregulation of Bmi-1 expression, and that bioactive components in black tea inhibited self-renewal of prostate CSCs/progenitor cells and downregulated the gene expression of Bmi-1. These promising preliminary studies provide experimental evidence to support the novel hypotheses that prostate CSCs are resistant to hormone ablation treatment, that hormone deprivation may accelerate self- renewal of prostate CSC in part via upregulation of Bmi-1, and that black tea bioactive components may delay CSC-originated and hormone deprivation-induced progression of androgen-independent prostate cancer in part by downregulation of Bmi-1. Specific aim 1 is to characterize cellular and molecular alterations in prostate CSCs derived from orthotopic prostate tumors at different stages of androgen deprivation-induced progression. The self-renewal capability of prostate CSCs at different stages of hormone deprivation-induced progression and associated Bmi-1 expression will be first determined (Aim 1A); then the functional role of Bmi-1 in prostate CSC response to androgen deprivation will be determined (Aim 1B). Specific aim 2 is to determine if androgen ablation accelerates prostate CSC self-renewal and tumorigenesis by upregulation of Bmi-1 in clinically relevant in vivo models. Specific aim 3 is to determine the effect of black tea components on prostate CSC- originated and androgen deprivation-induced prostate tumor progression. The research findings will provide crucial experimental evidence to support not only the essential role of prostate CSCs in the progression and recurrence of prostate cancer, but also a paradigm shift for identifying effective preventive and therapeutic regimens against progression of androgen-independent/hormone-refractory prostate cancer.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Tanshinones for prevention of bladder cancer progression
-
批准号:8296497
-
项目类别:
-
资助金额:$8.7万
-
财政年份:2011
-
负责人:JIN-RONG ZHOU
-
依托单位:
Targeting prostate cancer stem cells to delay prostate cancer progression
-
批准号:8190865
-
项目类别:
-
资助金额:$18.92万
-
财政年份:2011
-
负责人:JIN-RONG ZHOU
-
依托单位:
Tanshinones for prevention of bladder cancer progression
-
批准号:8203196
-
项目类别:
-
资助金额:$8.7万
-
财政年份:2011
-
负责人:JIN-RONG ZHOU
-
依托单位:
Metabolic Syndrome as Pancreatic Cancer Etiology
-
批准号:7469288
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2008
-
负责人:JIN-RONG ZHOU
-
依托单位:
Metabolic Syndrome as Pancreatic Cancer Etiology
-
批准号:7609157
-
项目类别:
-
资助金额:$22.95万
-
财政年份:2008
-
负责人:JIN-RONG ZHOU
-
依托单位:
Oldenlandia diffusa for prostate cancer treatment
-
批准号:7314416
-
项目类别:
-
资助金额:$17.0万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Parental metabolic status and offspring cancer risks
-
批准号:7491579
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Synergy between phytochemicals for prostate cancer prevention
-
批准号:7322669
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Oldenlandia diffusa for prostate cancer treatment
-
批准号:7503961
-
项目类别:
-
资助金额:$20.4万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Parental metabolic status and offspring cancer risks
-
批准号:7322672
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Synergy between phytochemicals for prostate cancer prevention
-
批准号:7491565
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Genistien and prevention of HER2-overexpressing breast *
-
批准号:6878387
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2004
-
负责人:JIN-RONG ZHOU
-
依托单位:
Genistien and prevention of HER2-overexpressing breast *
-
批准号:6951520
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2004
-
负责人:JIN-RONG ZHOU
-
依托单位:
Prevention of bladder cancer progression by sulforaphane
-
批准号:6878391
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2004
-
负责人:JIN-RONG ZHOU
-
依托单位:
Prevention of bladder cancer progression by sulforaphane
-
批准号:6951880
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2004
-
负责人:JIN-RONG ZHOU
-
依托单位:
Chemoprevention of Bladder Cancer by soybean
-
批准号:6575544
-
项目类别:
-
资助金额:$30.26万
-
财政年份:2003
-
负责人:JIN-RONG ZHOU
-
依托单位:
Genes Modulated by Soy in Prostate Cancer Progression
-
批准号:6618448
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2003
-
负责人:JIN-RONG ZHOU
-
依托单位:
Chemoprevention of Bladder CA by soybean bioactive comp.
-
批准号:7068530
-
项目类别:
-
资助金额:$29.55万
-
财政年份:2003
-
负责人:JIN-RONG ZHOU
-
依托单位:
Genes Modulated by Soy in Prostate Cancer Progression
-
批准号:6743739
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2003
-
负责人:JIN-RONG ZHOU
-
依托单位:
Chemoprevention of Bladder CA by soybean bioactive comp.
-
批准号:6897037
-
项目类别:
-
资助金额:$30.26万
-
财政年份:2003
-
负责人:JIN-RONG ZHOU
-
依托单位:
海外基金